乳腺癌治疗市场基于(关键地区、市场参与者、规模和份额)- 到 2030 年的预测

  • Report Code : TIPRE00030059
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 204
Buy Now

【研究报告】乳腺癌治疗市场规模预计将从2022年的310.7352亿美元增长到2030年的639.6705亿美元;预计 2022 年至 2030 年复合年增长率为 9.4%。
市场洞察和分析师观点:
乳腺癌治疗是一种通过使用化疗、靶向治疗、激素治疗等治疗方法来控制乳腺癌的方法、手术和各种药物。这些疗法有助于限制乳腺癌细胞的生长和增殖。全球患有乳腺癌的患者数量是加速市场增长的关键因素。此外,老牌公司在全球范围内不断推出新药也推动了市场的增长。此外,不断增长的乳腺癌治疗药物管道正在加剧乳腺癌治疗市场的竞争并推动投资。
增长动力:
个性化医疗、免疫疗法、联合疗法、药物输送系统、液体活检、人工智能和以患者为中心的方法有望塑造乳腺癌治疗的未来。这些趋势旨在改善治疗结果、减少副作用并提高乳腺癌患者的整体生活质量。
早期疾病检测在改善患者治疗结果和生存率方面发挥着重要作用。各种组织和医疗保健提供者正在实施筛查计划,以便在乳腺癌更容易治疗的初始阶段检测出乳腺癌。世界卫生组织于 2013 年 2 月发布了新的全球乳腺癌倡议框架,作为一项计划,旨在实现到 2040 年使 250 万人免遭乳腺癌侵害的目标。为了实现这一目标,新框架在世界癌症日之前公布该运动敦促各国遵循健康促进的三大支柱,以实现乳腺癌的早期发现、及时诊断和彻底管理。这些计划通常包括乳房X光检查、临床乳房检查和自我乳房检查,以识别乳腺癌的任何异常或体征。实施这些计划提高了人们对乳腺癌病例的认识和早期发现,从而对有效治疗方法提出了更高的需求。
此外,全球范围内见证了诊断技术的许多进步。美国国家医学图书馆指出,早期检测和精确诊断对于改善预后至关重要。乳腺癌评估经常使用放射成像方式,例如数字乳房 X 线摄影 (DM)、数字乳腺断层合成 (DBT)、磁共振成像 (MRI)、超声波和核医学程序。组织病理学 (HP) 是确定癌症是否存在的金标准。此外,使用人工智能(AI)技术定量描述医学图像对于改善乳腺癌分割、诊断和预后具有巨大潜力。这些技术帮助医疗保健提供者确定肿瘤的范围和特征,使他们能够制定个性化的治疗计划。因此,诊断和筛查项目的启动,加上诊断技术的进步,有助于乳腺癌治疗市场的增长。

Breast Cancer Therapeutics Market: Strategic Insights

Breast Cancer Therapeutics Market

  • CAGR (2022 - 2030)
    9.4%
  • Market Size 2022
    US$ 31.07 Billion
  • Market Size 2030
    US$ 63.97 Billion

Market Dynamics

GROWTH DRIVERS
  • 乳腺癌负担日益沉重
  • 启动多项诊断和筛查项目
FUTURE TRENDS
  • 越来越多地使用个性化医疗
OPPORTUNITIES
  • 政府和私人组织加大支持力度

Key Players

  • Eli Lilly and Co,
  • Eisai Co Ltd
  • Novartis AG
  • AstraZeneca Plc
  • Pfizer Inc
  • Gilead Sciences Inc
  • Merck & Co Inc
  • Genentech Inc
  • Teva Pharmaceutical Industries Ltd

Regional Overview

  • 北美
  • 欧洲
  • 亚太地区
  • 南美洲和中美洲
  • 中东和非洲

Market Segmentation

药物治疗
  • 靶向药物治疗
乳腺癌类型
  • 激素受体
  • HER2+ 和三阴性乳腺癌
分销渠道
  • 医院药房
  • 药店和零售药房
  • 网上药房
地理
  • 北美洲
  • 欧洲
  • 亚太地区
  • 中东和非洲
  • 南美洲和中美洲

报告细分和范围:
“乳腺癌治疗市场”根据药物治疗、乳腺癌类型、分销渠道和地理位置进行细分。根据药物治疗,市场分为靶向药物治疗、激素药物治疗、化疗和免疫治疗/生物治疗。就乳腺癌类型而言,乳腺癌治疗市场分为激素受体乳腺癌、HER2+乳腺癌和三阴性乳腺癌。根据分销渠道,市场分为医院药房、药店和零售药房以及网上药房。乳腺癌治疗市场根据地理位置分为北美(美国、加拿大和墨西哥)、欧洲(德国、法国、意大利、英国、西班牙和欧洲其他地区)、亚太地区(澳大利亚、中国) 、日本、印度、韩国和亚太其他地区)、中东和非洲(南非、沙特阿拉伯、阿联酋以及中东和非洲其他地区)以及南美洲和中美洲(巴西、阿根廷、以及南美洲和中美洲其他地区)。
细分分析:
乳腺癌治疗市场按药物治疗分为靶向药物治疗、激素药物治疗、化疗和免疫治疗/生物治疗。靶向药物治疗领域在 2022 年占据最大市场份额,预计 2022-2030 年市场复合年增长率最高。靶向药物通过破坏癌细胞或减缓其生长来阻止乳腺癌细胞的生长。目前,靶向治疗通常与传统化疗联合使用。靶向治疗有助于阻止异常蛋白质(例如 HER2)促进乳腺癌细胞生长的作用。靶向治疗分为abemaciclib、ado-trastuzumab emtansine、Palbociclib、trastuzumab等。对于实验室检查显示其乳腺肿瘤含有过量 HER2 的女性,可以开具曲妥珠单抗(赫赛汀)或拉帕替尼 (TYKERB)。 Kadcyla、Afinitor/Afinitor Disperz/Zortress 和 Lynparza 是一些关键的靶向治疗产品。 2023 年 8 月,美国食品和药物管理局 (FDA) 批准曲妥珠单抗 deruxtecan (Enhertu) 用于治疗 HER2 基因存在某种突变的成人非小细胞肺癌。它被认为是针对 HER2 突变肺癌的首个靶向疗法。
靶向疗法在发达国家和新兴国家治疗乳腺癌方面获得了显着的关注。随着新产品的推出和大量药物的上市,靶向治疗领域预计将在乳腺癌治疗市场中占据重要份额。
按药物治疗划分的乳腺癌治疗市场 – 2022 年和 2030 年
根据乳腺癌类型,乳腺癌治疗市场分为激素受体乳腺癌、HER2+乳腺癌和三阴性乳腺癌。激素受体细分市场在 2022 年占据最大的市场份额,预计在 2022 年至 2030 年期间将以最快的速度增长。雌激素和孕激素会促进多种乳腺癌的生长,称为激素敏感型或激素依赖性乳腺癌。激素受体是在乳腺癌细胞表面发现的蛋白质,它们与体内的激素相互作用,并在激素与其结合时被激活。激活的受体引发特定基因表达的变化,刺激细胞生长。激素疗法是激素受体阳性乳腺癌的常见治疗方法,包括 SERM 和芳香酶抑制剂,占所有发病病例的很大一部分。由于每年诊断出的乳腺癌病例数量不断增加,激素受体细分市场可能会出现增长。
根据分销渠道,乳腺癌治疗市场分为医院药房、药店和零售药房以及在线药房。医院药房细分市场在 2022 年占据最大市场份额。在线药房细分市场预计在 2022 年至 2030 年期间复合年增长率最高。医院药房在乳腺癌治疗的管理中发挥着至关重要的作用。他们负责配制和配药、监测药物安全、药物管理、患者教育和其他因素。乳腺癌是全世界最常见的癌症之一,对有效治疗方法的需求正在稳步增长。医院药房负责采购、储存和分发化疗药物和其他与乳腺癌相关的治疗药物,以确保患者及时接受正确的治疗。这些药店还有权管理这些药品的库存和储存,确保它们按照严格的规定储存和处理。他们与肿瘤学家和医疗团队的合作确保乳腺癌患者在整个治疗过程中获得最佳的个性化治疗和全面护理。医院药房在提供及时有效的乳腺癌治疗方面仍然发挥着重要作用,显着影响患者对抗疾病的结果。
患者对这些药房的化疗药物和治疗的管理高度依赖,患者对各种治疗的需求不断增长,并且医院药房药品供应的增加有利于该细分市场的增长。
区域分析:
根据地理位置,乳腺癌治疗市场分为五个关键区域:北美、欧洲、亚太地区、南部和中部美洲、中东和非洲。到 2022 年,北美在全球市场中占据重要份额。该地区的市场增长归因于乳腺癌患病率的上升以及开发新疗法的研发投资的增加。此外,越来越多的市场参与者正在扩大其在北美国家的地理足迹。乳腺癌是最常见的癌症类型之一,具有巨大的治疗市场。根据美国疾病控制与预防中心的数据,2020 年,美国女性新增乳腺癌病例 239,612 例,其中约 42,273 例死亡。每 10 万名女性中,就有 119 名新发乳腺癌病例,其中近 19 人死亡。此外,根据加拿大癌症协会的数据,到2022年,约有28,600名加拿大女性被诊断出患有乳腺癌,约占女性所有新发癌症病例的25%。
化疗、免疫治疗、靶向治疗和激素治疗是一种有效的治疗方法。可用的治疗方案很少。激素疗法旨在阻止支持特定形式乳腺癌生长的激素,而化疗则使用药物来破坏癌细胞。免疫疗法利用人体的免疫系统来对抗癌细胞,而靶向疗法则专注于与癌症生长有关的特定化学物质。美国乳腺癌的高患病率在一定程度上推动了对有效疗法的需求。
此外,医疗技术和研究的进步催生了突破性疗法的诞生,可以改善患者的治疗效果。辉瑞、诺华、罗氏、阿斯利康和礼来等几家大型制药公司主导着美国乳腺癌治疗市场。这些企业在研发方面进行了大量投资,以向市场推出新型和增强型药物。政府制定的法规和政策也会影响市场。用于乳腺癌治疗的新药物和疗法已获得美国食品和药物管理局 (FDA) 政府机构的批准。因此,在未来几年,乳腺癌治疗市场预计将进一步扩大。
行业发展和未来机遇:
全球乳腺癌治疗市场主要参与者采取的各种举措如下:< br>2023年2月,吉利德科学公司获得美国食品和药物管理局(FDA)批准Trodelvy(sacituzumab govitecan-hziy)用于治疗患有不可切除的局部晚期或转移性激素受体(HR)阳性、人类表皮细胞瘤的成年患者生长因子受体 2 (HER2) 阴性乳腺癌,在转移性环境中接受过内分泌治疗和至少两种额外的全身治疗。2022 年 11 月,礼来公司推出了 Ramiven (abemaciclib) 的额外适应症,此前获得印度药品监管总局(DCGI)批准,联合内分泌治疗用于激素受体(HR)阳性、HER2阴性、淋巴结阳性 EBC 高复发风险成人患者的辅助治疗。 2020 年 1 月,卫材有限公司在中国推出了自主研发的抗癌药物海乐卫(Halaven)。在中国,Halaven 获得了新药批准,用于治疗先前接受过至少两种化疗方案的局部晚期或转移性乳腺癌患者。竞争格局和主要公司:
礼来公司、卫材有限公司、诺华公司、阿斯利康公司、辉瑞公司、吉利德科学公司、默克公司、基因泰克公司、梯瓦制药工业有限公司和安进公司都是主要的乳腺癌治疗公司。这些公司专注于新技术、现有产品的进步以及地域扩张,以满足全球不断增长的消费者需求。

Breast Cancer Therapeutics Market Report Scope

Report Attribute Details
Market size in US$ 31.07 Billion
Market Size by US$ 63.97 Billion
Global CAGR
Historical Data 2020-2021
Forecast period 2023-2030
Segments Covered By 药物治疗
  • 靶向药物治疗
By 乳腺癌类型
  • 激素受体
  • HER2+ 和三阴性乳腺癌
By 分销渠道
  • 医院药房
  • 药店和零售药房
  • 网上药房
By 地理
  • 北美洲
  • 欧洲
  • 亚太地区
  • 中东和非洲
  • 南美洲和中美洲
Regions and Countries Covered 北美
  • 美国
  • 加拿大
  • 墨西哥
欧洲
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 意大利
  • 欧洲其他地区
亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太地区其他地区
南美洲和中美洲
  • 巴西
  • 阿根廷
  • 南美洲和中美洲其他地区
中东和非洲
  • 南非
  • 沙特阿拉伯
  • 阿联酋
  • 中东和非洲其他地区
Market leaders and key company profiles
  • Eli Lilly and Co,
  • Eisai Co Ltd
  • Novartis AG
  • AstraZeneca Plc
  • Pfizer Inc
  • Gilead Sciences Inc
  • Merck & Co Inc
  • Genentech Inc
  • Teva Pharmaceutical Industries Ltd
  • Report Coverage
    Report Coverage

    Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

    Segment Covered
    Segment Covered

    This text is related
    to segments covered.

    Regional Scope
    Regional Scope

    North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

    Country Scope
    Country Scope

    This text is related
    to country scope.

    Frequently Asked Questions


    What was the estimated breast cancer therapeutics market size in 2022?

    The breast cancer therapeutics market was valued at US$ 31,073.52 million in 2022.

    Which breast cancer type segment dominates the breast cancer therapeutics market?

    In 2022, the hormone receptor segment held the largest share of the market and is expected to grow at the fastest rate during the coming years. Hormone therapy is a common treatment for hormone receptor-positive breast cancer, including SERMs and aromatase inhibitors, representing a significant proportion of all incidence cases. The hormone receptor segment is likely to experience growth due to an increasing number of breast cancer cases diagnosed yearly.

    Who are the major players in the breast cancer therapeutics market?

    The breast cancer therapeutics market has major market players, including Eli Lilly and Co, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Genentech Inc., Teva Pharmaceutical Industries Ltd, and Amgen Inc.

    What factors drive the breast cancer therapeutics market?

    Key factors driving the market growth are growing burden of breast cancer and launch of several diagnostics and screening programs. However, high cost of diagnosis and treatments hinders the market growth.

    What is breast cancer therapeutics?

    Breast cancer is when the breast's cells proliferate out of control. Breast cancer comes in several forms. Which breast cells develop into cancer determines the type of breast cancer. The ducts or lobules are where most breast cancers start. Blood and lymph vessels are two ways breast cancer can travel outside the breast. Its treatment depends on the stage of cancer. It may consist of chemotherapy, radiation, hormone therapy and surgery.

    Which distribution channel segment dominates the breast cancer therapeutics market?

    In 2022, the hospital pharmacies segment held the largest share of the market. However, the online pharmacies segment is estimated to grow at the highest CAGR from 2022-2030. The hospital pharmacy plays a crucial role in managing breast cancer therapeutics. They are responsible for compounding and dispensing, monitoring drug safety, medication management, educating patients, and other factors. Breast cancer is one of the most widespread cancers worldwide, and the demand for effective therapeutics is steadily increasing.

    What are the growth estimates for the breast cancer therapeutics market till 2030?

    The breast cancer therapeutics market is expected to be valued at US$ 63,967.05 million in 2030.

    Which ulcer type segment dominates the breast cancer therapeutics market?

    The breast cancer therapeutics market, by drug therapy, is segmented into targeted drug therapy, hormonal drug therapy, chemotherapy, and immunotherapy/ biological therapy. In 2022, the targeted drug therapy segment held the largest share of the market and is expected to grow at the fastest rate during the coming years. Targeted drugs block the growth of breast cancer cells either by destroying cancer cells or slowing down their growth. Currently, targeted therapy is normally used in combination with traditional chemotherapy. Targeted therapy helps block the action of an abnormal protein (such as HER2) that promotes the growth of breast cancer cells.

    The List of Companies - Breast Cancer Therapeutics Market 

    1. Eli Lilly and Co,
    2. Eisai Co Ltd
    3. Novartis AG
    4. AstraZeneca Plc
    5. Pfizer Inc
    6. Gilead Sciences Inc
    7. Merck & Co Inc
    8. Genentech Inc
    9. Teva Pharmaceutical Industries Ltd
    10. Amgen Inc

    The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

    1. Data Collection and Secondary Research:

    As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

    Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

    1. Primary Research:

    The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

    For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

    A typical research interview fulfils the following functions:

    • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
    • Validates and strengthens in-house secondary research findings
    • Develops the analysis team’s expertise and market understanding

    Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

    • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
    • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

    Below is the breakup of our primary respondents by company, designation, and region:

    Research Methodology

    Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

    1. Data Analysis:

    Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

    • Macro-Economic Factor Analysis:

    We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

    • Country Level Data:

    Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

    • Company Profile:

    The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

    • Developing Base Number:

    Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

    1. Data Triangulation and Final Review:

    The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

    We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

    We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

    Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

    Related Reports